0.4423

2.31% 0.01

Pre-market: .44 -0.0023 -0.52%

Tilray Brands Inc (TLRY)

Overview News Price History Option Chain Financials Why TLRY Down? Discussions Forecast Stock Split

Tilray Brands Inc stock is traded at $0.4423, with a volume of 22.08M. It is up +2.31% in the last 24 hours and down -3.07% over the past month. Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure consists of CBD products and alcohol.

Previous Close:

$0.4323

Open:

$0.4386

24h Volume:

22.08M

Relative Volume:

0.65

Market Cap:

$493.22M

Revenue:

$829.22M

Net Income/Loss:

$-248.96M

P/E Ratio:

-1.4743

EPS:

-0.3

Net Cash Flow:

$-92.10M

1W Performance:

-8.90%

1M Performance:

-3.07%

6M Performance:

-70.32%

1Y Performance:

-77.32%

1-Day Range:

$0.432

$0.452

1-Week Range:

$0.4138

$0.49

52-Week Range:

$0.4138

$2.31

Tilray Brands Inc Stock (TLRY) Company Profile

Name

Tilray Brands Inc

Sector

Healthcare (1153)

Industry

Drug Manufacturers - Specialty & Generic (1)

Phone

519.322.8800

Address

655 MADISON AVENUE, NEW YORK

Employee

2,650

Twitter

@tilray

Next Earnings Date

2025-04-08

Latest SEC Filings

TLRY's Discussions on Twitter

Compare TLRY with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TLRY Tilray Brands Inc	0.4423	493.22M	829.22M	-248.96M	-92.10M	-0.30
ZTS Zoetis Inc	161.69	69.43B	9.29B	2.52B	2.28B	5.57
TAK Takeda Pharmaceutical Co Adr	14.27	47.30B	30.25B	1.37B	5.08B	0.4257
HLN Haleon Plc Adr	10.57	46.56B	14.35B	1.85B	0	0.4023
TEVA Teva Pharmaceutical Industries Ltd Adr	18.07	20.71B	16.54B	-1.64B	749.00M	-1.45
UTHR United Therapeutics Corp	308.00	13.25B	2.76B	1.11B	898.10M	22.77

Tilray Brands Inc Stock (TLRY) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-05-24	Reiterated	Alliance Global Partners	Neutral
Nov-02-22	Initiated	Bernstein	Mkt Perform
Jul-29-22	Downgrade	The Benchmark Company	Hold → Sell
Mar-04-22	Upgrade	Canaccord Genuity	Hold → Buy
Nov-18-21	Initiated	Barclays	Underweight
Nov-01-21	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jun-11-21	Downgrade	CIBC	Sector Outperform → Neutral
Jun-03-21	Upgrade	Cantor Fitzgerald	Neutral → Overweight
May-11-21	Resumed	Cowen	Outperform
May-07-21	Resumed	Jefferies	Buy
May-06-21	Initiated	Canaccord Genuity	Buy
Apr-28-21	Resumed	BofA Securities	Buy
Feb-18-21	Downgrade	Piper Sandler	Overweight → Neutral
Feb-18-21	Downgrade	The Benchmark Company	Buy → Hold
Nov-16-20	Downgrade	Jefferies	Hold → Underperform
Nov-11-20	Downgrade	Stifel	Hold → Sell
Oct-01-20	Reiterated	MKM Partners	Neutral
Sep-21-20	Upgrade	Jefferies	Underperform → Hold
May-12-20	Reiterated	The Benchmark Company	Buy
Apr-16-20	Downgrade	Jefferies	Hold → Underperform
Apr-09-20	Downgrade	Consumer Edge Research	Overweight → Equal Weight
Feb-24-20	Downgrade	Cowen	Outperform → Market Perform
Jan-13-20	Initiated	BofA/Merrill	Neutral
Nov-13-19	Reiterated	The Benchmark Company	Buy
Nov-05-19	Initiated	Cantor Fitzgerald	Neutral
Oct-22-19	Reiterated	Piper Jaffray	Overweight
Sep-20-19	Initiated	MKM Partners	Neutral
Aug-14-19	Reiterated	The Benchmark Company	Buy
Jul-17-19	Initiated	Ladenburg Thalmann	Neutral
Jun-28-19	Initiated	Consumer Edge Research	Overweight
Jun-06-19	Initiated	Stifel	Hold
Jun-05-19	Initiated	Oppenheimer	Perform
May-15-19	Upgrade	BMO Capital Markets	Underperform → Market Perform
May-13-19	Initiated	Alliance Global Partners	Neutral